A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 19 May 2016 The study is completed in Portugal and Outside EU/EEA.
- 30 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.